Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Collaboration revenue - related party	$ 17	$ 0	$ 33	$ 0
Operating expenses:
Research and development (including related party costs of $3,516 and $3,586 for the three months ended June 30, 2026 and 2025, respectively, and $3,798 and $7,656 for the six months ended June 30, 2026 and 2025, respectively)	7,767	10,029	13,048	19,310
General and administrative	6,739	6,769	12,972	13,885
Gain on lease modification	0	0	(6,882)	0
Total operating expenses	14,506	16,798	19,138	33,195
Loss from operations	(14,489)	(16,798)	(19,105)	(33,195)
Other income:
Interest income	55	270	156	664
Change in fair value of convertible notes - related party	271	0	271	0
Total other income	1,739	2,065	2,134	4,350
Net loss	(12,750)	(14,733)	(16,971)	(28,845)
Comprehensive loss	$ (12,750)	$ (14,733)	$ (16,971)	$ (28,845)
Net loss per share, basic (in dollars per share)	$ (0.41)	$ (0.56)	$ (0.55)	$ (1.59)
Net loss per share, diluted (in dollars per share)	$ (0.41)	$ (0.56)	$ (0.55)	$ (1.59)
Weighted-average number of shares used in computing net loss per share, basic (in shares)	31,144,754	26,081,273	31,058,642	18,091,478
Weighted-average number of shares used in computing net loss per share, diluted (in shares)	31,144,754	26,081,273	31,058,642	18,091,478
Related Party
Operating expenses:
Research and development (including related party costs of $3,516 and $3,586 for the three months ended June 30, 2026 and 2025, respectively, and $3,798 and $7,656 for the six months ended June 30, 2026 and 2025, respectively)	$ 3,516	$ 3,586	$ 3,798	$ 7,656
Other income:
GeneFab sublease income - related party	996	1,586	1,076	3,299
Change in fair value of convertible notes - related party			271	0
Nonrelated Party
Other income:
Other income, net	$ 417	$ 209	$ 631	$ 387